Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.38 |
| ▸ | LOX | P28300 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | IDH2 | P48735 | 1/20 | 0.32 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.32 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.32 |
| ▸ | VNN1 | O95497 | 1/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.31 |
| ▸ | FEN1 | P39748 | 1/20 | 0.31 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13611319 | 0.82 | LOXL2 (0.41) | LOXL2LOXPPARDIDO1SMARCA2 | |
| SCHEMBL25213572 | 0.74 | PTPN7 (0.46) | LOXL2LOXPPARDSMARCA2SMARCA4 | |
| SCHEMBL1662471 | 0.70 | LOXL2 (0.49) | LOXL2LOXIDO1GRIN1GRIN2B | |
| SCHEMBL27894825 | 0.69 | LOXL2 (0.50) | LOXL2LOXIDO1SMARCA2SMARCA4 | |
| SCHEMBL25248872 | 0.69 | PSEN1 (0.50) | LOXL2LOXSMARCA2SMARCA4MGLL | |
| SCHEMBL10200740 | 0.67 | LOXL2 (0.46) | LOXL2LOXIDO1GRIN1GRIN2B | |
| SCHEMBL7229589 | 0.67 | POLB (0.47) | — | |
| SCHEMBL22558604 | 0.67 | LOXL2 (0.59) | LOXL2LOXIDO1IDH2SMARCA2 | |
| SCHEMBL29769124 | 0.67 | LOXL2 (0.43) | LOXL2LOXALOX5APFEN1MGLL | |
| SCHEMBL24999942 | 0.67 | LOXL2 (0.43) | LOXL2LOXALOX5APFEN1MGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204109-A1 | Compounds | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2017-07-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170204109-A1 | Compounds | PLAAT2, PLA2G12A, PLA2G1B | LOXL2 210/4885LOX 151/4885PPARD 815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.